Patents by Inventor Kenneth Widder

Kenneth Widder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8410168
    Abstract: Compounds that cause reversible night blindness may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions. Such compounds and their derivatives may be used as single agent therapy or in combination with other agents or therapies.
    Type: Grant
    Filed: April 21, 2010
    Date of Patent: April 2, 2013
    Assignee: Acucela, Inc.
    Inventors: Kenneth Widder, Jay Lichter, Nathan L. Mata
  • Publication number: 20120309835
    Abstract: Described herein are methods and compositions for treating certain retinol-related diseases and conditions by modulation of transthyretin (TTR) and retinol binding protein (RBP) availability in the subject. For example, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies, metabolic disorders, idiopathic intracranial hypertension, hyperostosis, and protein misfolding and aggregation diseases. The compositions disclosed may be used as single agent therapy or in combination with other agents or therapies. In addition, described herein are methods and assays for selecting appropriate agents that can modulate the TTR and RBP availability in a subject.
    Type: Application
    Filed: December 7, 2011
    Publication date: December 6, 2012
    Applicant: ReVision Therapeutics, Inc.
    Inventors: Kenneth Widder, Jay Lichter, Nathan L. Mata
  • Patent number: 8314152
    Abstract: Compounds that cause reversible night blindness may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions. Such compounds and their derivatives may be used as single agent therapy or in combination with other agents or therapies.
    Type: Grant
    Filed: June 10, 2005
    Date of Patent: November 20, 2012
    Assignee: Acucela, Inc.
    Inventors: Kenneth Widder, Jay Lichter, Nathan L. Mata
  • Publication number: 20120288568
    Abstract: Compounds that reduce serum retinol, serum RBP, and/or serum retinol-RBP levels may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions. Such compounds and their derivatives may be used as single agent therapy or in combination with other agents or therapies.
    Type: Application
    Filed: May 17, 2012
    Publication date: November 15, 2012
    Applicant: Revision Therapeutics, Inc.
    Inventors: Kenneth Widder, Jay Lichter, Nathan L. Mata
  • Publication number: 20120238632
    Abstract: Described herein are methods and compositions for the detection of transthyretin (TTR), retinol binding protein (RBP) and retinol complex formation. The methods and compositions described herein also provide for the screening of modulators of retinol-RBP-TTR complex formation. Furthermore, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies.
    Type: Application
    Filed: September 13, 2011
    Publication date: September 20, 2012
    Applicant: ReVision Therapeutics, Inc.
    Inventors: Nathan L. Mata, Yun Han, Kenneth Widder, Jay Lichter
  • Publication number: 20120202885
    Abstract: Described herein are methods and compositions for treating certain retinol-related diseases and conditions by modulation of transthyretin (TTR) and retinol binding protein (RBP) availability in the subject. For example, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies, metabolic disorders, idiopathic intracranial hypertension, hyperostosis, and protein misfolding and aggregation diseases. The compositions disclosed may be used as single agent therapy or in combination with other agents or therapies. In addition, described herein are methods and assays for selecting appropriate agents that can modulate the TTR and RBP availability in a subject.
    Type: Application
    Filed: May 27, 2011
    Publication date: August 9, 2012
    Applicant: ReVision Therapeutics, Inc.
    Inventors: Kenneth Widder, Jay Lichter
  • Publication number: 20110294891
    Abstract: Compounds that cause reversible night blindness may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions. Such compounds and their derivatives may be used as single agent therapy or in combination with other agents or therapies.
    Type: Application
    Filed: May 27, 2011
    Publication date: December 1, 2011
    Applicant: ReVision Therapeutics, Inc.
    Inventors: Kenneth Widder, Jay Lichter, Nathan L. Mata
  • Publication number: 20100298443
    Abstract: Compounds that cause reversible night blindness may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions. Such compounds and their derivatives may be used as single agent therapy or in combination with other agents or therapies.
    Type: Application
    Filed: April 21, 2010
    Publication date: November 25, 2010
    Applicant: REVISION THERAPEUTICS, INC.
    Inventors: Kenneth WIDDER, Jay LICHTER, Nathan L. MATA
  • Publication number: 20090253665
    Abstract: Pharmaceutical compositions comprising an aldosterone inhibitor and an adenosine A1 receptor antagonist (AA1RA) and methods of treating cardiovascular disease comprising identifying a patient in need of such treatment, and administering a pharmaceutical composition disclosed herein to said patient are disclosed.
    Type: Application
    Filed: June 16, 2009
    Publication date: October 8, 2009
    Inventors: Lauren Otsuki, Kenneth Widder, Howard C. Dittrich
  • Publication number: 20090054532
    Abstract: Described herein are methods and compositions for the detection of transthyretin (TTR), retinol binding protein (RBP) and retinol complex formation. The methods and compositions described herein also provide for the screening of modulators of retinol-RBP-TTR complex formation. Furthermore, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies.
    Type: Application
    Filed: August 11, 2008
    Publication date: February 26, 2009
    Applicant: SIRION THERAPEUTICS, INC.
    Inventors: Nathan L. Mata, Yun Han, Kenneth Widder, Jay Lichter
  • Publication number: 20080254140
    Abstract: Described herein are combination methods, compositions and therapies for treating ophthalmic conditions or diseases arising from, associated with or leading to the overproduction of waste products in the visual cycle. Agents included within these combinations are 13-cis-retinyl derivatives; other agents included within these combinations are selected from vitamins, antioxidants, minerals, inducers of nitric oxide production, anti-inflammatory agents, and negatively-charged phospholipids. Such combination methods may be used as single or multiple administration therapies, or in combination with other agents or therapies.
    Type: Application
    Filed: August 18, 2005
    Publication date: October 16, 2008
    Inventors: Kenneth Widder, Jay Lichter
  • Patent number: 7432307
    Abstract: Described herein are methods and compositions for the detection of transthyretin (TTR), retinol binding protein (RBP) and retinol complex formation. The methods and compositions described herein also provide for the screening of modulators of retinol-RBP-TTR complex formation. Furthermore, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies.
    Type: Grant
    Filed: November 4, 2005
    Date of Patent: October 7, 2008
    Assignee: Sirion Therapeutics, Inc.
    Inventors: Nathan L. Mata, Kenneth Widder, Jay Lichter
  • Publication number: 20070015827
    Abstract: Compounds that reduce serum retinol, serum RBP, and/or serum retinol-RBP levels may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions. Such compounds and their derivatives may be used as single agent therapy or in combination with other agents or therapies.
    Type: Application
    Filed: July 10, 2006
    Publication date: January 18, 2007
    Applicant: Sytera, Inc.
    Inventors: Kenneth Widder, Jay Lichter, Nathan Mata
  • Publication number: 20060167088
    Abstract: Compounds that cause reversible night blindness may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions. Such compounds and their derivatives may be used as single agent therapy or in combination with other agents or therapies.
    Type: Application
    Filed: June 10, 2005
    Publication date: July 27, 2006
    Applicant: Sytera, Inc.
    Inventors: Kenneth Widder, Jay Lichter, Nathan Mata
  • Publication number: 20060135460
    Abstract: Described herein are methods and compositions for treating certain retinol-related diseases and conditions by modulation of transthyretin (TTR) and retinol binding protein (RBP) availability in the subject. For example, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies, metabolic disorders, idiopathic intracranial hypertension, hyperostosis, and protein misfolding and aggregation diseases. The compositions disclosed may be used as single agent therapy or in combination with other agents or therapies. In addition, described herein are methods and assays for selecting appropriate agents that can modulate the TTR and RBP availability in a subject.
    Type: Application
    Filed: December 8, 2005
    Publication date: June 22, 2006
    Applicant: Sytera, Inc.
    Inventors: Kenneth Widder, Jay Lichter
  • Publication number: 20060099714
    Abstract: Disclosed herein are methods and devices for detecting fluorescent molecules that are relevant to the health of the eye and related tissues. The presence of such molecules in the eye and related tissues can be used to diagnose whether the patient has certain diseases, including the macular degenerations and macular dystrophies. The amount of such molecules in the eye and related tissues can be used to determine the extent and stage of these diseases, to monitor the progress of these diseases, to design treatment strategies, to monitor the effectiveness of such treatments and to develop new therapies.
    Type: Application
    Filed: October 25, 2005
    Publication date: May 11, 2006
    Applicant: Sytera, Inc.
    Inventors: Nathan Mata, Kenneth Widder, Jay Lichter
  • Publication number: 20060094063
    Abstract: Described herein are methods and compositions for the detection of transthyretin (TTR), retinol binding protein (RBP) and retinol complex formation. The methods and compositions described herein also provide for the screening of modulators of retinol-RBP-TTR complex formation. Furthermore, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies.
    Type: Application
    Filed: November 4, 2005
    Publication date: May 4, 2006
    Applicant: Sytera, Inc.
    Inventors: Nathan Mata, Yun Han, Kenneth Widder, Jay Lichter
  • Publication number: 20060058355
    Abstract: Disclosed is a pharmaceutical composition comprising a calcium channel blocker and an angiotensin II receptor blocker or an angiotensin converting enzyme inhibitor. Also disclosed is a method of treating cardiovascular disease or renal disease comprising identifying a patient in need of such treatment, and administering a pharmaceutical composition disclosed herein to said patient.
    Type: Application
    Filed: August 23, 2005
    Publication date: March 16, 2006
    Inventors: Howard Dittrich, Lauren Otsuki, Kenneth Widder
  • Publication number: 20060035911
    Abstract: Disclosed is a pharmaceutical composition comprising a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, and a non-adenosine modifying diuretic. Also disclosed are methods of inducing a diuretic effect in an animal comprising the step of administering a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, in combination with second pharmaceutical composition capable of inducing a diuretic effect.
    Type: Application
    Filed: October 11, 2005
    Publication date: February 16, 2006
    Inventors: Kenneth Widder, Lauren Otsuki, Howard Dittrich, Scott Thomson, Roland Blantz
  • Publication number: 20060030572
    Abstract: Disclosed is a pharmaceutical composition comprising a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, and a non-adenosine modifying diuretic. Also disclosed are methods of inducing a diuretic effect in an animal comprising the step of administering a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, in combination with second pharmaceutical composition capable of inducing a diuretic effect.
    Type: Application
    Filed: October 11, 2005
    Publication date: February 9, 2006
    Inventors: Kenneth Widder, Lauren Otsuki, Howard Dittrich, Scott Thomson, Roland Blantz